Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses. | Exp Hematol Oncol | 2024 | 38553748 | PubTator, text mining | PubMed |
| The Role of Coinhibitory Receptors in B Cell Dysregulation in SARS-CoV-2-Infected Individuals with Severe Disease. | J Immunol | 2024 | 38517295 | PubTator, text mining | PubMed |
| Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. | ESMO Open | 2024 | 38503143 | PubTator, text mining | PubMed |
| Expression and function of VISTA on myeloid cells. | Biochem Pharmacol | 2024 | 38428824 | PubTator, text mining | PubMed |
| Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors. | J Med Chem | 2024 | 38412237 | PubTator, text mining | PubMed |
| Validation of the interaction between PRDX4 and TXNDC5 in gastric cancer and the significance of the PRDX4 gene in gastric cancer based on a data mining analysis. | Transl Cancer Res | 2024 | 38410208 | PubTator, text mining | PubMed |
| Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. | Front Immunol | 2024 | 38384461 | PubTator, text mining | PubMed |
| Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma. | Front Immunol | 2024 | 38357542 | PubTator, text mining | PubMed |
| Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer. | Clin Transl Med | 2024 | 38356419 | PubTator, text mining | PubMed |
| The B7:CD28 family and friends: Unraveling coinhibitory interactions. | Immunity | 2024 | 38354702 | PubTator, text mining | PubMed |
| Prognostic implication of novel immune-related signature in breast cancer. | Medicine (Baltimore) | 2024 | 38335435 | PubTator, text mining | PubMed |
| Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. | Front Immunol | 2024 | 38322267 | PubTator, text mining | PubMed |
| Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity. | J Immunother Cancer | 2024 | 38296598 | PubTator, text mining | PubMed |
| Effects of N6-methyladenosine modification on metabolic reprogramming in digestive tract tumors. | Heliyon | 2024 | 38293446 | PubTator, text mining | PubMed |
| SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation. | Clin Transl Med | 2024 | 38279869 | PubTator, text mining | PubMed |
| Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma. | Cancers (Basel) | 2024 | 38275876 | PubTator, text mining | PubMed |
| The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors. | Cancers (Basel) | 2024 | 38275869 | PubTator, text mining | PubMed |
| Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach. | Biomedicines | 2024 | 38255322 | PubTator, text mining | PubMed |
| Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. | Cancers (Basel) | 2024 | 38254772 | PubTator, text mining | PubMed |
| Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes. | Mol Cancer | 2024 | 38254110 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=14